Snap Bio Inc., of San Diego, and Torrey Pines Investment (TPI) reported that their joint early drug discovery program within the framework of the i2020 Accelerator has resulted in achieving the projected milestone in developing several small-molecule lead candidates for treatment of hepatocellular carcinoma and hepatoblastoma.